Supply shortages and insurance hurdles for GLP-1 agonists due to high drug prices leave many people with diabetes and obesity without essential medicines, impacting their health and well-being.
The high costs set by drugmakers make it challenging for adults, including those with insurance, to afford GLP-1 drugs, with those with the lowest incomes facing the most significant financial burden.
Novo Nordisk and Eli Lilly charge around $1,000 for a month's supply of Ozempic and Mounjaro, respectively, contributing to high costs for patients before insurance coverage.
Medicare spending on popular diabetes and weight loss drugs is substantial, highlighting the financial impact and burden on both patients and healthcare systems.
[
add
]
[
|
|
...
]